192 related articles for article (PubMed ID: 26151044)
21. Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
Ma Z; Bolinger AA; Chen H; Zhou J
J Med Chem; 2023 Aug; 66(16):10991-11026. PubMed ID: 37578463
[TBL] [Abstract][Full Text] [Related]
22. The Role of Methyltransferase NSD2 as a Potential Oncogene in Human Solid Tumors.
Chen R; Chen Y; Zhao W; Fang C; Zhou W; Yang X; Ji M
Onco Targets Ther; 2020; 13():6837-6846. PubMed ID: 32764971
[TBL] [Abstract][Full Text] [Related]
23. The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling.
Tanaka H; Igata T; Etoh K; Koga T; Takebayashi SI; Nakao M
Aging Cell; 2020 Jul; 19(7):e13173. PubMed ID: 32573059
[TBL] [Abstract][Full Text] [Related]
24. The catalytic domain of the histone methyltransferase NSD2/MMSET is required for the generation of B1 cells in mice.
Dobenecker MW; Marcello J; Becker A; Rudensky E; Bhanu NV; Carrol T; Garcia BA; Prinjha R; Yurchenko V; Tarakhovsky A
FEBS Lett; 2020 Oct; 594(20):3324-3337. PubMed ID: 32862441
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
[TBL] [Abstract][Full Text] [Related]
27. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
[TBL] [Abstract][Full Text] [Related]
28. Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and
Jin X; Wang Y; Chen J; Niu M; Yang Y; Zhang Q; Bao G
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2289355. PubMed ID: 38059332
[TBL] [Abstract][Full Text] [Related]
29. H3K36me2 methyltransferase NSD2 orchestrates epigenetic reprogramming during spermatogenesis.
Li Z; Zhang X; Xie S; Liu X; Fei C; Huang X; Tang Y; Zhou LQ
Nucleic Acids Res; 2022 Jul; 50(12):6786-6800. PubMed ID: 35736136
[TBL] [Abstract][Full Text] [Related]
30. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
[TBL] [Abstract][Full Text] [Related]
31. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
32. Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives.
Tisi D; Chiarparin E; Tamanini E; Pathuri P; Coyle JE; Hold A; Holding FP; Amin N; Martin AC; Rich SJ; Berdini V; Yon J; Acklam P; Burke R; Drouin L; Harmer JE; Jeganathan F; van Montfort RL; Newbatt Y; Tortorici M; Westlake M; Wood A; Hoelder S; Heightman TD
ACS Chem Biol; 2016 Nov; 11(11):3093-3105. PubMed ID: 27571355
[TBL] [Abstract][Full Text] [Related]
33. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.
Wang GG; Cai L; Pasillas MP; Kamps MP
Nat Cell Biol; 2007 Jul; 9(7):804-12. PubMed ID: 17589499
[TBL] [Abstract][Full Text] [Related]
34. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Kim JY; Kee HJ; Choe NW; Kim SM; Eom GH; Baek HJ; Kook H; Kook H; Seo SB
Mol Cell Biol; 2008 Mar; 28(6):2023-34. PubMed ID: 18172012
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
Hanley RP; Nie DY; Tabor JR; Li F; Sobh A; Xu C; Barker NK; Dilworth D; Hajian T; Gibson E; Szewczyk MM; Brown PJ; Barsyte-Lovejoy D; Herring LE; Wang GG; Licht JD; Vedadi M; Arrowsmith CH; James LI
J Am Chem Soc; 2023 Apr; 145(14):8176-8188. PubMed ID: 36976643
[TBL] [Abstract][Full Text] [Related]
36. A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences.
McDevitt PJ; Schneck JL; Diaz E; Hou W; Huddleston MJ; Matico RE; McCormick PM; Kirkpatrick RB
Protein Expr Purif; 2019 Dec; 164():105455. PubMed ID: 31306746
[TBL] [Abstract][Full Text] [Related]
37. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
38. NSD family proteins: Rising stars as therapeutic targets.
He L; Cao Y; Sun L
Cell Insight; 2024 Apr; 3(2):100151. PubMed ID: 38371593
[TBL] [Abstract][Full Text] [Related]
39. Depletion of Nsd2-mediated histone H3K36 methylation impairs adipose tissue development and function.
Zhuang L; Jang Y; Park YK; Lee JE; Jain S; Froimchuk E; Broun A; Liu C; Gavrilova O; Ge K
Nat Commun; 2018 May; 9(1):1796. PubMed ID: 29728617
[TBL] [Abstract][Full Text] [Related]
40. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
